Esketamine - Johnson & Johnson

Drug Profile

Esketamine - Johnson & Johnson

Alternative Names: JNJ-54135419; S-ketamine

Latest Information Update: 07 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Johnson & Johnson
  • Class Analgesics; Antidepressants; Chlorobenzenes; Cyclohexanones; General anaesthetics; Small molecules
  • Mechanism of Action NMDA receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Major depressive disorder

Most Recent Events

  • 06 Nov 2017 Janssen completes the phase III TRANSFORM-2 trial in Major depressive disorder (Combination therapy, Treatment-resistant) in Czech Republic, Poland, Spain, USA, Germany (Intranasal) (NCT02418585)
  • 28 Oct 2017 Janssen Research and Development completes the phase III SUSTAIN-2 trial for Major depressive disorder (Treatment-resistant, Combination therapy) in USA, United Kingdom, Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Finland, France, Germany, Italy, Lithuania, Malaysia, Mexico, Poland, Romania, South Africa, South Korea, Spain, Sweden, Turkey and Taiwan (Intranasal) (NCT02497287)
  • 05 Oct 2017 Phase-II clinical trials in Major depressive disorder (In adolescents, Adjunctive treatment) in Spain, Hungary (Intranasal) (NCT03185819)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top